Pablo Lapuerta, M.D., has been appointed chief medical officer at Lexicon Pharmaceuticals, Inc. Dr. Lapuerta will be responsible for directing clinical development of drug candidates from Phase II proof-of-concept through Phase III and approval.
Dr. Lapuerta has 15 years of pharmaceutical industry experience in a variety of leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas. Most recently, he served as vice president at Bristol-Myers Squibb, where he was responsible for global development of an Alzheimer’s disease drug candidate associated with the use of an innovative biomarker.
“Dr. Lapuerta’s extensive experience in clinical development, regulatory strategy, and medical affairs are especially valuable as we progress the four programs we currently have in mid-stage clinical studies,” said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. “His breadth of knowledge in multiple therapeutic areas meshes well with Lexicon’s broad pipeline in drug discovery and development.”